MDWD
MediWound Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$12.70
+7.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.04
From 52W high−35.50%
Volume189411.00
Market cap$163.96M
P/E (TTM)—
P/S (TTM)13.8x
Div yield—
Key dataOct 19, 2026
Open
$12.04
From 52W high
−35.50%
Volume
189411.00
Market cap
$163.96M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.3x
P/E (TTM)
—
RSI (14)
40.5
MomentumView details →
1D Return
+7.17%
YTD Return
−33.32%
SummaryUpdated Jun 1, 2026
MediWound Ltd. (NASDAQ:MDWD) is an Israeli biopharmaceutical company founded in 2000 and headquartered in Yavne, Israel. The company went public on NASDAQ in March 2014. MediWound specializes in developing, manufacturing, and commercializing novel enzymatic bio-therapeutic solutions for tissue repair and regeneration, with a primary focus on wound debridement - the medical process of removing dead, damaged, or infected tissue to promote healing.
Similar companies
Latest newsMore news →
MediWound was awarded an additional $3.3 million by the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid.27d agoMediWound announced that the independent Data and Safety Monitoring Board completed a pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended the study continue without modification.35d agoMediWound reported a Q2 2026 net loss of $0.77 per share, compared to a loss of $1.23 per share a year ago.67d ago